We are live on ! Find out more
LRMR icon

Larimar Therapeutics
LRMR

44 hedge funds and large institutions have $289M invested in Larimar Therapeutics in 2014 Q3 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,900% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 1

909% more capital invested

Capital invested by funds: $28.6M → $289M (+$260M)

780% more funds holding

Funds holding: 5 → 44 (+39)

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
44
Holders Change
+39
Holders Change %
+780%
% of All Funds
1.27%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
40
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRV
Third Rock Ventures
Massachusetts
+$106M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$61.8M
3
Franklin Resources
Franklin Resources
California
+$14.5M
4
RCM
RA Capital Management
Massachusetts
+$13.8M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$9.03M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.18M
2
Citadel Advisors
Citadel Advisors
Florida
-$313K

LRMR Hedge Fund Activity: Q3 2014 in Review

44 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2014, worth a combined $289M — up 909% from $28.6M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new LRMR positions and 1 closed out — a net gain of 39 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Third Rock Ventures, opening a new position worth an estimated $106M. The largest seller was Alyeska Investment Group, cutting an estimated $1.18M.

  • 44 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2014, up from 5 in Q2 2014.
  • Funds reported $289M of Larimar Therapeutics stock for Q3 2014, up 909% quarter-over-quarter.
  • 40 funds opened new Larimar Therapeutics positions in Q3 2014 and 1 closed out, a net change of +39 holders.
  • The largest Larimar Therapeutics buyer in Q3 2014 was Third Rock Ventures, an estimated $106M added.
  • The largest Larimar Therapeutics seller in Q3 2014 was Alyeska Investment Group, an estimated $1.18M sold.

Based on aggregated 13F filings for Q3 2014.